Genetic Risk Factors for Adverse Drug Reactions

The use of medicines may in some cases be associated with the development drug-induced diseases (DIDs) аnd other adverse drug reactions (ADRs), which leads to an increase morbidity/mortality rates, and/or symptoms forcing a patient seek medical attention or resulting hospitalisation. ADRs develop due changes patient’s genotype, entail inadequate pharmacological response. aim study was analyse and summarise literature data on genetic risk factors that cause DIDs ADRs. It shown polymorphism genes encoding enzymes metabolism (CYP, UGT, NAT, TPMT, EPHX, GST, etc.) carriers (transporters) drugs (P-gp, BCRP, MRP, OATP, OCT, can change pharmacokinetics drugs, affecting their activity. Polymorphism RYR1, CACNA1S, MT-RNR1, VKORC1 , receptors targeted by human leukocyte antigen ( HLA ) gene, affect pharmacodynamics modifying targets changing sensitivity biological pathways effects medicines. Changes pharmacogenetic tests will allow personalised approach patients’ treatment prevention timely detection potential during therapy. Before prescribing medicines, clinicians should recommendations dosing based tests, are posted official websites Pharmacogenomics Research Network (PGRN), Knowledgebase (PharmGKB), Clinical Pharmacogenetics Implementation Consortium (CPIC). results ongoing clinical studies effect gene safety soon for higher personalisation choice pharmacotherapy many ADRs, including DIDs.